NCT02948283View on ClinicalTrials.gov

Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

September 5, 2017

Primary Completion Date

December 1, 2017

Study Completion Date

December 1, 2017

Conditions
AnemiaFatigueFeverLymphadenopathyLymphocytosisNight SweatsRecurrent Chronic Lymphocytic LeukemiaRecurrent Plasma Cell MyelomaRefractory Chronic Lymphocytic LeukemiaRefractory Plasma Cell MyelomaSplenomegalyThrombocytopeniaWeight Loss
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Metformin Hydrochloride

Given PO

OTHER

Pharmacological Study

Correlative studies

DRUG

Ritonavir

Given PO

OTHER

Quality-of-Life

Ancillary studies

OTHER

Questionnaire

Ancillary studies

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter